Study to investigate the natriuretic effects, safety, tolerability and pharmacokinetics of BAY94-8862
Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.
- Healthy male white subjects - 18 to 46 years of age - Body mass index (BMI): 18 - 29.9 kg/m²
- Clinically relevant findings in medical history or in the physical examination - Systolic blood pressure below 100 or above 140 mmHg - Diastolic blood pressure below 50 or above 90 mmHg - Heart rate below 45 or above 95 beats / min
Neuss, Germany, 41460
E-mail: [email protected]
Phone: (+)1-888-84 22937
Study to investigate the effectiveness of different single oral doses of BAY94-8862 on natriuresis after administration of 0.5 mg fludrocortisone (Astonin H®) with 50 mg eplerenone (Inspra®) as active control in healthy male subjects in a randomized, single-blind, placebo-controlled, combined 3-fold crossover and parallel-group design